BioLargo Statistics
Total Valuation
BioLargo has a market cap or net worth of 63.15 million. The enterprise value is 61.12 million.
Market Cap | 63.15M |
Enterprise Value | 61.12M |
Important Dates
The last earnings date was Wednesday, May 14, 2025.
Earnings Date | May 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
BioLargo has 303.61 million shares outstanding. The number of shares has increased by 3.63% in one year.
Current Share Class | 303.61M |
Shares Outstanding | 303.61M |
Shares Change (YoY) | +3.63% |
Shares Change (QoQ) | +0.02% |
Owned by Insiders (%) | 6.13% |
Owned by Institutions (%) | 0.04% |
Float | 261.33M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 3.88 |
PB Ratio | 12.41 |
P/TBV Ratio | 8.30 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -19.42 |
EV / Sales | 3.75 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -10.38 |
Financial Position
The company has a current ratio of 2.14, with a Debt / Equity ratio of 0.60.
Current Ratio | 2.14 |
Quick Ratio | 2.01 |
Debt / Equity | 0.60 |
Debt / EBITDA | n/a |
Debt / FCF | -0.52 |
Interest Coverage | -63.14 |
Financial Efficiency
Return on equity (ROE) is -107.31% and return on invested capital (ROIC) is -45.36%.
Return on Equity (ROE) | -107.31% |
Return on Assets (ROA) | -33.38% |
Return on Invested Capital (ROIC) | -45.36% |
Return on Capital Employed (ROCE) | -76.07% |
Revenue Per Employee | 387,810 |
Profits Per Employee | -74,929 |
Employee Count | 44 |
Asset Turnover | 1.60 |
Inventory Turnover | 29.65 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.36% in the last 52 weeks. The beta is 0.19, so BioLargo's price volatility has been lower than the market average.
Beta (5Y) | 0.19 |
52-Week Price Change | -24.36% |
50-Day Moving Average | 0.24 |
200-Day Moving Average | 0.24 |
Relative Strength Index (RSI) | 42.65 |
Average Volume (20 Days) | 394,106 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioLargo had revenue of 16.29 million and -3.15 million in losses. Loss per share was -0.01.
Revenue | 16.29M |
Gross Profit | 7.10M |
Operating Income | -5.43M |
Pretax Income | -5.49M |
Net Income | -3.15M |
EBITDA | -5.23M |
EBIT | -5.43M |
Loss Per Share | -0.01 |
Balance Sheet
The company has 2.56 million in cash and 3.05 million in debt, giving a net cash position of -489,000 or -0.00 per share.
Cash & Cash Equivalents | 2.56M |
Total Debt | 3.05M |
Net Cash | -489,000 |
Net Cash Per Share | -0.00 |
Equity (Book Value) | 5.09M |
Book Value Per Share | 0.03 |
Working Capital | 3.85M |
Cash Flow
In the last 12 months, operating cash flow was -5.52 million and capital expenditures -372,000, giving a free cash flow of -5.89 million.
Operating Cash Flow | -5.52M |
Capital Expenditures | -372,000 |
Free Cash Flow | -5.89M |
FCF Per Share | -0.02 |
Margins
Gross margin is 43.56%, with operating and profit margins of -33.34% and -19.32%.
Gross Margin | 43.56% |
Operating Margin | -33.34% |
Pretax Margin | -33.72% |
Profit Margin | -19.32% |
EBITDA Margin | -32.13% |
EBIT Margin | -33.34% |
FCF Margin | n/a |
Dividends & Yields
BioLargo does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -3.63% |
Shareholder Yield | n/a |
Earnings Yield | -4.98% |
FCF Yield | -9.33% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |